Review Note
Last Update: 07/28/2024 09:22 PM
Current Deck: SK EBM Deck
Published
Fields:
Text
The following two trials showed the benefits of {{c1::finerenone::non-steroidal mineralocorticoid receptor antagonist}} in patients with CKD and T2DM:
- {{c2::FIDELIO-CKD::2020 RCT}}: Patients w/ eGFR 25-60 w/ moderate proteinuria or eGFR 25-75 w/ severe proteinuria; primary outcome of renal failure, sustained decrease in eGFR, or death from renal causes
- {{c3::FIGARO-CKD::2021 RCT}}: Patients with more mild CKD (eGFR up to 90 depending on proteinuria); primary outcome of death from CV causes, nonfatal MI or stroke, or hospitalization for HF
Extra
ankihub_id
d7cfe9ec-3422-4093-919b-cf4b2b0e6279
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: